nodes	percent_of_prediction	percent_of_DWPC	metapath
Metolazone—CA5B—cervicothoracic ganglion—systemic scleroderma	0.173	0.718	CbGeAlD
Metolazone—CA7—digestive system—systemic scleroderma	0.00872	0.0362	CbGeAlD
Metolazone—CA12—connective tissue—systemic scleroderma	0.00785	0.0326	CbGeAlD
Metolazone—CA9—digestive system—systemic scleroderma	0.00766	0.0318	CbGeAlD
Metolazone—CA9—tendon—systemic scleroderma	0.00729	0.0303	CbGeAlD
Metolazone—SLC12A3—lung—systemic scleroderma	0.00714	0.0297	CbGeAlD
Metolazone—CA12—digestive system—systemic scleroderma	0.00567	0.0235	CbGeAlD
Metolazone—CA5B—tendon—systemic scleroderma	0.00484	0.0201	CbGeAlD
Metolazone—CA12—lung—systemic scleroderma	0.00473	0.0197	CbGeAlD
Metolazone—CA5B—lung—systemic scleroderma	0.00425	0.0176	CbGeAlD
Metolazone—CA4—digestive system—systemic scleroderma	0.00351	0.0146	CbGeAlD
Metolazone—CA4—tendon—systemic scleroderma	0.00334	0.0139	CbGeAlD
Metolazone—CA4—lung—systemic scleroderma	0.00293	0.0122	CbGeAlD
Metolazone—Nausea—Pentoxifylline—systemic scleroderma	0.000972	0.00128	CcSEcCtD
Metolazone—Chills—Mycophenolate mofetil—systemic scleroderma	0.000972	0.00128	CcSEcCtD
Metolazone—Malaise—Lisinopril—systemic scleroderma	0.000971	0.00128	CcSEcCtD
Metolazone—Vertigo—Lisinopril—systemic scleroderma	0.000967	0.00127	CcSEcCtD
Metolazone—Diarrhoea—Mometasone—systemic scleroderma	0.000966	0.00127	CcSEcCtD
Metolazone—Hypokalaemia—Prednisone—systemic scleroderma	0.000966	0.00127	CcSEcCtD
Metolazone—Syncope—Lisinopril—systemic scleroderma	0.000965	0.00127	CcSEcCtD
Metolazone—Leukopenia—Lisinopril—systemic scleroderma	0.000964	0.00127	CcSEcCtD
Metolazone—Shock—Mycophenolic acid—systemic scleroderma	0.00096	0.00126	CcSEcCtD
Metolazone—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000955	0.00126	CcSEcCtD
Metolazone—Palpitations—Lisinopril—systemic scleroderma	0.000951	0.00125	CcSEcCtD
Metolazone—Loss of consciousness—Lisinopril—systemic scleroderma	0.000946	0.00125	CcSEcCtD
Metolazone—Cough—Lisinopril—systemic scleroderma	0.000939	0.00124	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000931	0.00123	CcSEcCtD
Metolazone—Anorexia—Mycophenolic acid—systemic scleroderma	0.00093	0.00122	CcSEcCtD
Metolazone—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.000929	0.00122	CcSEcCtD
Metolazone—Tension—Mycophenolate mofetil—systemic scleroderma	0.000925	0.00122	CcSEcCtD
Metolazone—Insomnia—Leflunomide—systemic scleroderma	0.000925	0.00122	CcSEcCtD
Metolazone—Abdominal distension—Prednisone—systemic scleroderma	0.000924	0.00122	CcSEcCtD
Metolazone—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.000924	0.00122	CcSEcCtD
Metolazone—Paraesthesia—Leflunomide—systemic scleroderma	0.000918	0.00121	CcSEcCtD
Metolazone—Arthralgia—Lisinopril—systemic scleroderma	0.000916	0.00121	CcSEcCtD
Metolazone—Chest pain—Lisinopril—systemic scleroderma	0.000916	0.00121	CcSEcCtD
Metolazone—Nervousness—Mycophenolate mofetil—systemic scleroderma	0.000916	0.00121	CcSEcCtD
Metolazone—Anxiety—Lisinopril—systemic scleroderma	0.000913	0.0012	CcSEcCtD
Metolazone—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000912	0.0012	CcSEcCtD
Metolazone—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000907	0.00119	CcSEcCtD
Metolazone—Discomfort—Lisinopril—systemic scleroderma	0.000905	0.00119	CcSEcCtD
Metolazone—Lethargy—Methotrexate—systemic scleroderma	0.000905	0.00119	CcSEcCtD
Metolazone—Dyspepsia—Leflunomide—systemic scleroderma	0.0009	0.00119	CcSEcCtD
Metolazone—Pancreatitis—Prednisone—systemic scleroderma	0.0009	0.00118	CcSEcCtD
Metolazone—Vomiting—Mometasone—systemic scleroderma	0.000898	0.00118	CcSEcCtD
Metolazone—Dry mouth—Lisinopril—systemic scleroderma	0.000896	0.00118	CcSEcCtD
Metolazone—Feeling abnormal—Azathioprine—systemic scleroderma	0.000892	0.00118	CcSEcCtD
Metolazone—Rash—Mometasone—systemic scleroderma	0.000891	0.00117	CcSEcCtD
Metolazone—Asthenia—Captopril—systemic scleroderma	0.00089	0.00117	CcSEcCtD
Metolazone—Dermatitis—Mometasone—systemic scleroderma	0.00089	0.00117	CcSEcCtD
Metolazone—Decreased appetite—Leflunomide—systemic scleroderma	0.000889	0.00117	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000889	0.00117	CcSEcCtD
Metolazone—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000885	0.00117	CcSEcCtD
Metolazone—Headache—Mometasone—systemic scleroderma	0.000885	0.00117	CcSEcCtD
Metolazone—Insomnia—Mycophenolic acid—systemic scleroderma	0.000882	0.00116	CcSEcCtD
Metolazone—Fatigue—Leflunomide—systemic scleroderma	0.000881	0.00116	CcSEcCtD
Metolazone—Pruritus—Captopril—systemic scleroderma	0.000878	0.00116	CcSEcCtD
Metolazone—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000876	0.00115	CcSEcCtD
Metolazone—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000875	0.00115	CcSEcCtD
Metolazone—Pain—Leflunomide—systemic scleroderma	0.000874	0.00115	CcSEcCtD
Metolazone—Constipation—Leflunomide—systemic scleroderma	0.000874	0.00115	CcSEcCtD
Metolazone—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000872	0.00115	CcSEcCtD
Metolazone—Somnolence—Mycophenolic acid—systemic scleroderma	0.000867	0.00114	CcSEcCtD
Metolazone—Agitation—Mycophenolate mofetil—systemic scleroderma	0.000867	0.00114	CcSEcCtD
Metolazone—Shock—Lisinopril—systemic scleroderma	0.000864	0.00114	CcSEcCtD
Metolazone—Thrombocytopenia—Lisinopril—systemic scleroderma	0.00086	0.00113	CcSEcCtD
Metolazone—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000859	0.00113	CcSEcCtD
Metolazone—Abdominal pain—Azathioprine—systemic scleroderma	0.000856	0.00113	CcSEcCtD
Metolazone—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000851	0.00112	CcSEcCtD
Metolazone—Diarrhoea—Captopril—systemic scleroderma	0.000849	0.00112	CcSEcCtD
Metolazone—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000848	0.00112	CcSEcCtD
Metolazone—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000847	0.00112	CcSEcCtD
Metolazone—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000846	0.00111	CcSEcCtD
Metolazone—Erectile dysfunction—Prednisone—systemic scleroderma	0.000845	0.00111	CcSEcCtD
Metolazone—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000844	0.00111	CcSEcCtD
Metolazone—Feeling abnormal—Leflunomide—systemic scleroderma	0.000843	0.00111	CcSEcCtD
Metolazone—Fatigue—Mycophenolic acid—systemic scleroderma	0.000841	0.00111	CcSEcCtD
Metolazone—Nausea—Mometasone—systemic scleroderma	0.000839	0.0011	CcSEcCtD
Metolazone—Anorexia—Lisinopril—systemic scleroderma	0.000837	0.0011	CcSEcCtD
Metolazone—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000836	0.0011	CcSEcCtD
Metolazone—Pain—Mycophenolic acid—systemic scleroderma	0.000834	0.0011	CcSEcCtD
Metolazone—Constipation—Mycophenolic acid—systemic scleroderma	0.000834	0.0011	CcSEcCtD
Metolazone—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000833	0.0011	CcSEcCtD
Metolazone—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000829	0.00109	CcSEcCtD
Metolazone—Hyperglycaemia—Prednisone—systemic scleroderma	0.000828	0.00109	CcSEcCtD
Metolazone—Cough—Mycophenolate mofetil—systemic scleroderma	0.000823	0.00108	CcSEcCtD
Metolazone—Dizziness—Captopril—systemic scleroderma	0.00082	0.00108	CcSEcCtD
Metolazone—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000814	0.00107	CcSEcCtD
Metolazone—Urticaria—Leflunomide—systemic scleroderma	0.000812	0.00107	CcSEcCtD
Metolazone—Abdominal pain—Leflunomide—systemic scleroderma	0.000808	0.00106	CcSEcCtD
Metolazone—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000804	0.00106	CcSEcCtD
Metolazone—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000803	0.00106	CcSEcCtD
Metolazone—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000803	0.00106	CcSEcCtD
Metolazone—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000802	0.00106	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.0008	0.00105	CcSEcCtD
Metolazone—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.0008	0.00105	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000799	0.00105	CcSEcCtD
Metolazone—Hypersensitivity—Azathioprine—systemic scleroderma	0.000798	0.00105	CcSEcCtD
Metolazone—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000798	0.00105	CcSEcCtD
Metolazone—Insomnia—Lisinopril—systemic scleroderma	0.000795	0.00105	CcSEcCtD
Metolazone—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000793	0.00104	CcSEcCtD
Metolazone—Paraesthesia—Lisinopril—systemic scleroderma	0.000789	0.00104	CcSEcCtD
Metolazone—Vomiting—Captopril—systemic scleroderma	0.000789	0.00104	CcSEcCtD
Metolazone—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000785	0.00103	CcSEcCtD
Metolazone—Rash—Captopril—systemic scleroderma	0.000782	0.00103	CcSEcCtD
Metolazone—Dermatitis—Captopril—systemic scleroderma	0.000781	0.00103	CcSEcCtD
Metolazone—Somnolence—Lisinopril—systemic scleroderma	0.000781	0.00103	CcSEcCtD
Metolazone—Headache—Captopril—systemic scleroderma	0.000777	0.00102	CcSEcCtD
Metolazone—Dyspepsia—Lisinopril—systemic scleroderma	0.000773	0.00102	CcSEcCtD
Metolazone—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000771	0.00102	CcSEcCtD
Metolazone—Decreased appetite—Lisinopril—systemic scleroderma	0.000764	0.00101	CcSEcCtD
Metolazone—Fatigue—Lisinopril—systemic scleroderma	0.000757	0.000998	CcSEcCtD
Metolazone—Shock—Mycophenolate mofetil—systemic scleroderma	0.000757	0.000997	CcSEcCtD
Metolazone—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000754	0.000993	CcSEcCtD
Metolazone—Hypersensitivity—Leflunomide—systemic scleroderma	0.000753	0.000992	CcSEcCtD
Metolazone—Pancreatitis—Methotrexate—systemic scleroderma	0.000752	0.00099	CcSEcCtD
Metolazone—Pain—Lisinopril—systemic scleroderma	0.000751	0.000989	CcSEcCtD
Metolazone—Constipation—Lisinopril—systemic scleroderma	0.000751	0.000989	CcSEcCtD
Metolazone—Diarrhoea—Azathioprine—systemic scleroderma	0.000741	0.000976	CcSEcCtD
Metolazone—Nausea—Captopril—systemic scleroderma	0.000737	0.00097	CcSEcCtD
Metolazone—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000735	0.000968	CcSEcCtD
Metolazone—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000734	0.000966	CcSEcCtD
Metolazone—Asthenia—Leflunomide—systemic scleroderma	0.000734	0.000966	CcSEcCtD
Metolazone—Feeling abnormal—Lisinopril—systemic scleroderma	0.000724	0.000953	CcSEcCtD
Metolazone—Pruritus—Leflunomide—systemic scleroderma	0.000723	0.000953	CcSEcCtD
Metolazone—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000718	0.000946	CcSEcCtD
Metolazone—Dizziness—Azathioprine—systemic scleroderma	0.000716	0.000943	CcSEcCtD
Metolazone—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000706	0.00093	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000701	0.000924	CcSEcCtD
Metolazone—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.0007	0.000922	CcSEcCtD
Metolazone—Asthenia—Mycophenolic acid—systemic scleroderma	0.0007	0.000922	CcSEcCtD
Metolazone—Diarrhoea—Leflunomide—systemic scleroderma	0.0007	0.000921	CcSEcCtD
Metolazone—Urticaria—Lisinopril—systemic scleroderma	0.000698	0.000919	CcSEcCtD
Metolazone—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000696	0.000917	CcSEcCtD
Metolazone—Abdominal pain—Lisinopril—systemic scleroderma	0.000694	0.000915	CcSEcCtD
Metolazone—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000691	0.00091	CcSEcCtD
Metolazone—Pruritus—Mycophenolic acid—systemic scleroderma	0.00069	0.000909	CcSEcCtD
Metolazone—Vomiting—Azathioprine—systemic scleroderma	0.000688	0.000907	CcSEcCtD
Metolazone—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000684	0.000901	CcSEcCtD
Metolazone—Drowsiness—Methotrexate—systemic scleroderma	0.000684	0.0009	CcSEcCtD
Metolazone—Rash—Azathioprine—systemic scleroderma	0.000683	0.000899	CcSEcCtD
Metolazone—Dermatitis—Azathioprine—systemic scleroderma	0.000682	0.000898	CcSEcCtD
Metolazone—Headache—Azathioprine—systemic scleroderma	0.000678	0.000893	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000678	0.000893	CcSEcCtD
Metolazone—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000678	0.000892	CcSEcCtD
Metolazone—Dizziness—Leflunomide—systemic scleroderma	0.000676	0.00089	CcSEcCtD
Metolazone—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000669	0.000881	CcSEcCtD
Metolazone—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000667	0.000879	CcSEcCtD
Metolazone—Pain—Mycophenolate mofetil—systemic scleroderma	0.000658	0.000867	CcSEcCtD
Metolazone—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000658	0.000867	CcSEcCtD
Metolazone—Vomiting—Leflunomide—systemic scleroderma	0.00065	0.000856	CcSEcCtD
Metolazone—Hypersensitivity—Lisinopril—systemic scleroderma	0.000647	0.000852	CcSEcCtD
Metolazone—Dizziness—Mycophenolic acid—systemic scleroderma	0.000645	0.000849	CcSEcCtD
Metolazone—Epistaxis—Methotrexate—systemic scleroderma	0.000645	0.000849	CcSEcCtD
Metolazone—Rash—Leflunomide—systemic scleroderma	0.000645	0.000849	CcSEcCtD
Metolazone—Dermatitis—Leflunomide—systemic scleroderma	0.000644	0.000848	CcSEcCtD
Metolazone—Nausea—Azathioprine—systemic scleroderma	0.000643	0.000847	CcSEcCtD
Metolazone—Headache—Leflunomide—systemic scleroderma	0.00064	0.000844	CcSEcCtD
Metolazone—Agranulocytosis—Methotrexate—systemic scleroderma	0.000638	0.00084	CcSEcCtD
Metolazone—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000634	0.000835	CcSEcCtD
Metolazone—Asthenia—Lisinopril—systemic scleroderma	0.00063	0.00083	CcSEcCtD
Metolazone—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000629	0.000829	CcSEcCtD
Metolazone—Pruritus—Lisinopril—systemic scleroderma	0.000622	0.000819	CcSEcCtD
Metolazone—Vomiting—Mycophenolic acid—systemic scleroderma	0.00062	0.000817	CcSEcCtD
Metolazone—Rash—Mycophenolic acid—systemic scleroderma	0.000615	0.00081	CcSEcCtD
Metolazone—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000614	0.000809	CcSEcCtD
Metolazone—Hepatitis—Methotrexate—systemic scleroderma	0.000614	0.000808	CcSEcCtD
Metolazone—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000611	0.000805	CcSEcCtD
Metolazone—Headache—Mycophenolic acid—systemic scleroderma	0.000611	0.000805	CcSEcCtD
Metolazone—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000608	0.000801	CcSEcCtD
Metolazone—Nausea—Leflunomide—systemic scleroderma	0.000607	0.0008	CcSEcCtD
Metolazone—Vision blurred—Prednisone—systemic scleroderma	0.000602	0.000794	CcSEcCtD
Metolazone—Diarrhoea—Lisinopril—systemic scleroderma	0.000601	0.000792	CcSEcCtD
Metolazone—Ill-defined disorder—Prednisone—systemic scleroderma	0.000593	0.000781	CcSEcCtD
Metolazone—Anaemia—Prednisone—systemic scleroderma	0.000591	0.000778	CcSEcCtD
Metolazone—Agitation—Prednisone—systemic scleroderma	0.000587	0.000774	CcSEcCtD
Metolazone—Dizziness—Lisinopril—systemic scleroderma	0.000581	0.000765	CcSEcCtD
Metolazone—Erythema multiforme—Methotrexate—systemic scleroderma	0.00058	0.000764	CcSEcCtD
Metolazone—Nausea—Mycophenolic acid—systemic scleroderma	0.000579	0.000763	CcSEcCtD
Metolazone—Malaise—Prednisone—systemic scleroderma	0.000577	0.000759	CcSEcCtD
Metolazone—Vertigo—Prednisone—systemic scleroderma	0.000574	0.000756	CcSEcCtD
Metolazone—Syncope—Prednisone—systemic scleroderma	0.000573	0.000755	CcSEcCtD
Metolazone—Tinnitus—Methotrexate—systemic scleroderma	0.000572	0.000754	CcSEcCtD
Metolazone—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000567	0.000747	CcSEcCtD
Metolazone—Loss of consciousness—Prednisone—systemic scleroderma	0.000562	0.00074	CcSEcCtD
Metolazone—Vomiting—Lisinopril—systemic scleroderma	0.000559	0.000736	CcSEcCtD
Metolazone—Rash—Lisinopril—systemic scleroderma	0.000554	0.00073	CcSEcCtD
Metolazone—Dermatitis—Lisinopril—systemic scleroderma	0.000553	0.000729	CcSEcCtD
Metolazone—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000552	0.000727	CcSEcCtD
Metolazone—Hypertension—Prednisone—systemic scleroderma	0.000552	0.000727	CcSEcCtD
Metolazone—Chills—Methotrexate—systemic scleroderma	0.000551	0.000725	CcSEcCtD
Metolazone—Headache—Lisinopril—systemic scleroderma	0.00055	0.000725	CcSEcCtD
Metolazone—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000545	0.000717	CcSEcCtD
Metolazone—Arthralgia—Prednisone—systemic scleroderma	0.000544	0.000717	CcSEcCtD
Metolazone—Anxiety—Prednisone—systemic scleroderma	0.000542	0.000714	CcSEcCtD
Metolazone—Discomfort—Prednisone—systemic scleroderma	0.000538	0.000708	CcSEcCtD
Metolazone—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000527	0.000694	CcSEcCtD
Metolazone—Dysgeusia—Methotrexate—systemic scleroderma	0.000523	0.000689	CcSEcCtD
Metolazone—Nausea—Lisinopril—systemic scleroderma	0.000522	0.000687	CcSEcCtD
Metolazone—Back pain—Methotrexate—systemic scleroderma	0.000517	0.000681	CcSEcCtD
Metolazone—Shock—Prednisone—systemic scleroderma	0.000513	0.000676	CcSEcCtD
Metolazone—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000509	0.00067	CcSEcCtD
Metolazone—Vision blurred—Methotrexate—systemic scleroderma	0.000504	0.000663	CcSEcCtD
Metolazone—Anorexia—Prednisone—systemic scleroderma	0.000497	0.000655	CcSEcCtD
Metolazone—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000496	0.000653	CcSEcCtD
Metolazone—Anaemia—Methotrexate—systemic scleroderma	0.000494	0.00065	CcSEcCtD
Metolazone—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000489	0.000645	CcSEcCtD
Metolazone—Rash—Mycophenolate mofetil—systemic scleroderma	0.000485	0.000639	CcSEcCtD
Metolazone—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000485	0.000639	CcSEcCtD
Metolazone—Headache—Mycophenolate mofetil—systemic scleroderma	0.000482	0.000635	CcSEcCtD
Metolazone—Malaise—Methotrexate—systemic scleroderma	0.000482	0.000635	CcSEcCtD
Metolazone—Vertigo—Methotrexate—systemic scleroderma	0.00048	0.000632	CcSEcCtD
Metolazone—Leukopenia—Methotrexate—systemic scleroderma	0.000478	0.00063	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000475	0.000626	CcSEcCtD
Metolazone—Insomnia—Prednisone—systemic scleroderma	0.000472	0.000622	CcSEcCtD
Metolazone—Paraesthesia—Prednisone—systemic scleroderma	0.000469	0.000617	CcSEcCtD
Metolazone—Cough—Methotrexate—systemic scleroderma	0.000466	0.000614	CcSEcCtD
Metolazone—Dyspepsia—Prednisone—systemic scleroderma	0.000459	0.000605	CcSEcCtD
Metolazone—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000457	0.000602	CcSEcCtD
Metolazone—Arthralgia—Methotrexate—systemic scleroderma	0.000455	0.000599	CcSEcCtD
Metolazone—Chest pain—Methotrexate—systemic scleroderma	0.000455	0.000599	CcSEcCtD
Metolazone—Decreased appetite—Prednisone—systemic scleroderma	0.000454	0.000597	CcSEcCtD
Metolazone—Fatigue—Prednisone—systemic scleroderma	0.00045	0.000592	CcSEcCtD
Metolazone—Discomfort—Methotrexate—systemic scleroderma	0.000449	0.000592	CcSEcCtD
Metolazone—Constipation—Prednisone—systemic scleroderma	0.000446	0.000588	CcSEcCtD
Metolazone—Feeling abnormal—Prednisone—systemic scleroderma	0.00043	0.000566	CcSEcCtD
Metolazone—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000427	0.000562	CcSEcCtD
Metolazone—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000427	0.000562	CcSEcCtD
Metolazone—Anorexia—Methotrexate—systemic scleroderma	0.000416	0.000547	CcSEcCtD
Metolazone—Urticaria—Prednisone—systemic scleroderma	0.000414	0.000546	CcSEcCtD
Metolazone—Abdominal pain—Prednisone—systemic scleroderma	0.000412	0.000543	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000397	0.000523	CcSEcCtD
Metolazone—Insomnia—Methotrexate—systemic scleroderma	0.000394	0.000519	CcSEcCtD
Metolazone—Paraesthesia—Methotrexate—systemic scleroderma	0.000392	0.000516	CcSEcCtD
Metolazone—Somnolence—Methotrexate—systemic scleroderma	0.000388	0.000511	CcSEcCtD
Metolazone—Hypersensitivity—Prednisone—systemic scleroderma	0.000384	0.000506	CcSEcCtD
Metolazone—Dyspepsia—Methotrexate—systemic scleroderma	0.000384	0.000506	CcSEcCtD
Metolazone—Decreased appetite—Methotrexate—systemic scleroderma	0.000379	0.000499	CcSEcCtD
Metolazone—Fatigue—Methotrexate—systemic scleroderma	0.000376	0.000495	CcSEcCtD
Metolazone—Asthenia—Prednisone—systemic scleroderma	0.000374	0.000493	CcSEcCtD
Metolazone—Pain—Methotrexate—systemic scleroderma	0.000373	0.000491	CcSEcCtD
Metolazone—Pruritus—Prednisone—systemic scleroderma	0.000369	0.000486	CcSEcCtD
Metolazone—Feeling abnormal—Methotrexate—systemic scleroderma	0.000359	0.000473	CcSEcCtD
Metolazone—Diarrhoea—Prednisone—systemic scleroderma	0.000357	0.00047	CcSEcCtD
Metolazone—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000357	0.00047	CcSEcCtD
Metolazone—Urticaria—Methotrexate—systemic scleroderma	0.000346	0.000456	CcSEcCtD
Metolazone—Dizziness—Prednisone—systemic scleroderma	0.000345	0.000454	CcSEcCtD
Metolazone—Abdominal pain—Methotrexate—systemic scleroderma	0.000345	0.000454	CcSEcCtD
Metolazone—Vomiting—Prednisone—systemic scleroderma	0.000332	0.000437	CcSEcCtD
Metolazone—Rash—Prednisone—systemic scleroderma	0.000329	0.000433	CcSEcCtD
Metolazone—Dermatitis—Prednisone—systemic scleroderma	0.000329	0.000433	CcSEcCtD
Metolazone—Headache—Prednisone—systemic scleroderma	0.000327	0.00043	CcSEcCtD
Metolazone—Hypersensitivity—Methotrexate—systemic scleroderma	0.000321	0.000423	CcSEcCtD
Metolazone—Asthenia—Methotrexate—systemic scleroderma	0.000313	0.000412	CcSEcCtD
Metolazone—Nausea—Prednisone—systemic scleroderma	0.00031	0.000408	CcSEcCtD
Metolazone—Pruritus—Methotrexate—systemic scleroderma	0.000309	0.000406	CcSEcCtD
Metolazone—Diarrhoea—Methotrexate—systemic scleroderma	0.000298	0.000393	CcSEcCtD
Metolazone—Dizziness—Methotrexate—systemic scleroderma	0.000288	0.00038	CcSEcCtD
Metolazone—Vomiting—Methotrexate—systemic scleroderma	0.000277	0.000365	CcSEcCtD
Metolazone—Rash—Methotrexate—systemic scleroderma	0.000275	0.000362	CcSEcCtD
Metolazone—Dermatitis—Methotrexate—systemic scleroderma	0.000275	0.000362	CcSEcCtD
Metolazone—Headache—Methotrexate—systemic scleroderma	0.000273	0.00036	CcSEcCtD
Metolazone—Nausea—Methotrexate—systemic scleroderma	0.000259	0.000341	CcSEcCtD
